Participants 91 184 6
patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase
Participants 413 485 4
patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Participants 507 612 6
A total of 476 patients were randomly assigned 2:1 to imatinib 800 mg (n = 319) or 400 mg (n = 157) daily
